RecruitingPhase II/IIIEN originalLeukemia

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax to the current standard of care stem cell transplant regimen of busulfan, fludarabine, and cladribine may help to control high-risk acute myeloid leukemia or myelodysplastic syndrome.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek od 18 do 70 lat
  • Białaczka mieloidalna z wcześniejszym leczeniem i cechami wysokiego ryzyka
  • Zespół mielodysplastyczny lub przewlekła białaczka mielomonocytowa z cechami wysokiego ryzyka
  • Dostępny dawca do przeszczepu: rodzeństwo, darczyńca niespokrewniony lub spokrewniony
  • Potwierdzona świadoma zgoda na udział w badaniu
  • Ujemny test ciążowy u kobiet w wieku rozrodczym
  • Prawidłowa funkcja wątroby i nerek potwierdzona badaniami krwi

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Maximum age
70 Years
Last updated (source)
August 11, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (1)

M D Anderson Cancer Center

Houston, United States

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.